Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 79 The GLP-1 segment accounts for 3% of total diabetes care market value in Region AAMEO GLP-1 value in bDKK Region AAMEO GLP-1 market VictozaⓇ Exenatide Dulaglutide Lixisenatide CAGR value¹: 23.1% VictozaⓇ value market share in Region AAMEO VictozaⓇ Exenatide Dulaglutide Lixisenatide 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Aug 2013 1 CAGR for 5-year period AAMEO: Africa, Asia, the Middle East and Oceania Source: IQVIA monthly MAT Aug, 2018 value figures (DKK) changing diabetes Share of total diabetes care market GLP-1 value market share 2% 100% 80% 1% 60% 1% 40% 0% 20% -1% 0% Aug 2018 Aug 2013 Source: IQVIA monthly MAT Aug, 2018 value figures (DKK) Aug 2018 .44% 33% -23% novo nordisk

View entire presentation